A few days ago, the American food and drug administration announced that they had already approved the HIV vaccine that will replace the ARVs that people living with HIV take daily. According to the report, this vaccine will be injected into HIV-positive people twice a year at a cost.
Photo courtesy, image used for illustration purposes only.
A report has emerged that this vaccine will be sold to patients for 42,250 dollars per year, which is approximately 5.1 million Kenya shillings. These patients will also have to be an additional 39,000 dollars as maintenance costs. This means that patients will be paying around ten million Kenyan shillings per year.
Photo courtesy, image used for evidence purposes only.
This vaccine will serve as hope to all people living with HIV for the cure is still being searched for by these scientists who discovered the vaccine. Please share your thoughts on this report in the comments section below. Please do like, comment and share.
Content created and supplied by: LiveUpdates (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More